News >

Risk Factor Profile Determined for Development of Pediatric TA-TMA After HSCT

Virginia Powers, PhD
Published: Tuesday, Apr 02, 2019

The development of high-grade acute graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation (HSCT) poses the highest risk for transplant-associated thrombotic microangiopathy (TA-TMA) in pediatric patients, according to retrospective results presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.1

“TA-TMA might represent a form of vascular acute GVHD; therefore, continuing control of acute GVHD, including the use of calcineurin inhibitors, may be important to prevent worsening of TA-TMA associated with GVHD,” Elfeky remarked.


  1. Elfeky R, Lucchini G, Lum SH, et al. New insights into risk factors for transplant-associated thrombotic microangiopathy (TA-TMA) in paediatric HSCT. Presented at: 2019 European Society for Blood and Marrow Transplantation Annual Meeting; March 24 to 27, 2019; Frankfurt, Germany. Abstract B287.
  2. Jodele S, Khoury JC, Goebel J, et al. Clinical utility of diagnostic criteria for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TMA): a prospective single center study. Biol Blood Marrow Transp. 2013;19(2):S249. doi: 10.1016/j.bbmt.2012.11.327.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication